Publications Archives - Page 3 of 7

egnite Launches CardioCare Research Suite to Accelerate Patient Identification for Leading Cardiovascular Clinical Trials

July 1, 2025

ALISO VIEJO, Calif. – July 1, 2025 – egnite, Inc., a leading digital health company advancing cardiovascular innovation, today announced the launch of its new CardioCare Research Suite, a significant expansion of its flagship platform that enables hospitals to automatically identify patients eligible for clinical trials across participating health systems.

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?

March 13, 2025

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient

Figure 1: Observed Mortality Stratified by GLP-1 RA and/or SGLT2i Prescription

Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis

March 10, 2025

BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized,

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams

November 25, 2024

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their

Contemporary Diagnosis, Management, and Outcomes of Patients With Low-Gradient Severe Aortic Stenosis: A Multi-Center Analysis

November 11, 2024

BACKGROUND The American College of Cardiology/American Heart Association guidelines recommend assessing aortic stenosis (AS) using American Society of Echocardiography-endorsed parameters and referring patients with severe symptomatic AS for treatment. Yet, multi-site real-world assessment of guideline adherence is lacking. METHODS We assessed consecutive echocardiographic reports for patients >18 years of age